Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-Risk Prostate Cancer Treated With Radical Radiotherapy.

Trial Profile

Randomized Adjuvant Phase III Trial of Six Cycles of Docetaxel+Hormonal Treatment Versus Hormonal Treatment in Patients With Intermediate or High-Risk Prostate Cancer Treated With Radical Radiotherapy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Docetaxel (Primary) ; Gonadotropin releasing hormone stimulants
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms AdRad
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 1 Aug 2017 to 30 Aug 2020.
    • 06 Nov 2017 Planned primary completion date changed from 1 Aug 2017 to 30 Aug 2020.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top